Are AnteoTech (ASX:ADO) rapid COVID tests available in Australia?

The company's rapid testing device still isn't able to be used in Australia.

| More on:
a woman inserts a swab up her nostril while conducting a rapid antigen test for COVID-19 in her home.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The AnteoTech Ltd (ASX: ADO) share price has soared since the start of the pandemic as the company has worked to create a COVID-19 rapid antigen test.

Enthusiasm surrounding the now-developed point-of-care rapid testing device has helped boost the company's stock by more than 1000% since the start of 2020.

AnteoTech's EuGeni testing device is now reportedly widely used in the United States and Europe. However, the Queensland-based company's test is facing ongoing delays for Australian approvals, much to the frustration of AnteoTech's boss.

At the time of writing, the AnteoTech share price is 31.5 cents, 3.28% higher than its previous close.

For context, the S&P/ASX 200 Index (ASX:XJO) is up 0.86% right now.

Is the AnteoTech COVID rapid test locked in TGA delays?

AnteoTech's calls for more rapid testing have been answered, but the company's product still can't be found in Australia.

AnteoTech CEO Derek Thomson reportedly told Queensland's The Courier Mail, the company pushed the state government to accept rapid tests as a measure to screen for the virus. Last week, the publication quoted Thomson as saying:

We've always said that rapid testing has a place to be used to control the pandemic and now we're seeing that play out…

There's too much stress on the PCR testing system in all Australian states and it's really not necessary to go to the full extent of doing a PCR test when you've got rapid tests readily available now.

Days after Thomson's comments, Queensland Premier Annastacia Palaszczuk declared the state would allow arriving travellers' entry after they receive a negative rapid test. Previously, arrivals had to receive a negative PCR test.

Further, Palaszczuk announced close contacts in Queensland will soon be given access to 18 million free rapid antigen tests at COVID-19 testing sites yesterday, saying:

We know the transition to RAT tests for close contacts will reduce some of the pressure we have seen at testing clinics in recent weeks, ensuring those with symptoms can be tested sooner.

Still, Thomson reportedly noted it's "quite frustrating" the Therapeutic Goods Administration hasn't approved the use of the AnteoTech's COVID-19 rapid antigen test.

That's despite the potential its approval could lead to millions more 15-minute tests being made available to Australians. The EuGeni testing device has been proven to be accurate 97.3% of the time.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Why CSL shares could be a bargain buy at $240

Let's see what Bell Potter is saying about this blue chip.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 ASX companies that are global leaders

Numerous ASX companies have extended their reach beyond Australia to dominate in their fields.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »